LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis
LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis
复制标题
DOI：
10.1002/ijc.25689
复制
发表时间：
2011-08-01
影响因子：
6.4
通讯作者：
Zhou, Rouli
中科院分区：
文献类型：
--
作者：
Yin, Mingzhu;Xu, Ye;Zhou, Rouli
LAPTM 4 B是一个新的肿瘤相关基因。到目前为止，还没有关于LAPTM 4 B表达在上皮性卵巢癌转移中的作用的公开数据。因此，本研究旨在确定LAPTM 4 B过表达是否是上皮性卵巢癌转移的新预测因子。采用免疫印迹法和免疫组化法检测22例正常卵巢组织和139例卵巢癌组织中LAPTM 4 B的表达。采用单因素和多因素分析来确定LAPTM 4 B表达与上皮性卵巢癌转移之间的关系。免疫组化结果显示，59例LAPTM 4 B过表达的卵巢癌患者中，57例（96.6%）有腹腔转移，31例（52.5%）有淋巴结转移。单因素和多因素分析结果表明，LAPTM 4 B过表达与转移有关。腹腔转移和淋巴结转移的OR值分别为11.410（95%CI：2.357，55.239）和6.332（95%CI：2.533，15.831）。LAPTM 4 B过表达对腹腔转移的敏感性和特异性分别为48.7%和90.9%，对淋巴结转移的敏感性和特异性分别为73.8%和71.1%。LAPTM 4 B过表达是卵巢上皮癌转移的新预测因子，也是卵巢癌早期诊断的重要潜在生物标志物。
LAPTM4B is a novel tumor-associated gene. To date, there have been no published data regarding the role of LAPTM4B expression in epithelial ovarian carcinoma metastasis. Therefore, this study was performed to determine whether LAPTM4B overexpression is a new predictor of epithelial ovarian carcinoma metastasis. LAPTM4B expression was evaluated in 22 normal ovarian specimens and 139 ovarian carcinomas by western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were used to determine the association between LAPTM4B expression and epithelial ovarian carcinoma metastasis. Western blotting analysis demonstrated that LAPTM4B was overexpressed in metastatic tissues from patients with ovarian cancers, and immunohistochemistry results revealed that among 59 patients with LAPTM4B overexpression, 57 (96.6%) presented intraperitoneal metastasis and 31 (52.5%) had lymph node metastasis. The results of the univariate and multivariate analyses demonstrated that LAPTM4B overexpression correlated with metastasis. The odds ratio of high-to-low expression for intraperitoneal metastasis was 11.410 (95% CI: 2.357, 55.239) and that for lymph node metastasis was 6.332 (95% CI: 2.533, 15.831). For intraperitoneal metastasis, the sensitivity and specificity of LAPTM4B overexpression were 48.7% and 90.9%; for lymph node metastasis, they were 73.8%% and 71.1%, respectively. LAPTM4B overexpression is a new predictor of epithelial ovarian carcinoma metastasis and an important potential biomarker for the early diagnosis of ovarian carcinoma.